Intracoronary administration of abciximab during percutaneous coronary interventions: Should this be the routine and preferred approach?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 2, 2006, Pages 136-141

  Sharma, Sanjiv ^a,d   Makkar, Raj ^b   Lardizabal, Joel ^c  

^a CA and Bakersfield Heart Hospital   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c KERN MEDICAL CENTER   (United States)

^d Bakersfield Heart Hospital   (United States)

Author keywords

Abciximab; Intracoronary; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CD11B ANTIGEN; CD40 LIGAND; CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR; VITRONECTIN;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; EMBOLISM; FEMALE; FLOW KINETICS; GRAFT OCCLUSION; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT; THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CLINICAL TRIALS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 33748989298     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406288761     Document Type: Article

References (28)

1. The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
3. Lincoff AM,Califf RM, Moliterno DJ, et al. Complimentary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999; 341:319-327.
4. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors. Recognition of a two edged sword? Circulation. 2002; 106:379-385.
5. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
6. Mitchel JF, Alberghini TV. Site specific thrombolysis with ReoPro. Circulation. 1996;94:I202.
7. Mitchel JF, Alberghini TV. Local delivery of ReoPro: pharmacokinetics and effect on platelet deposition following balloon angioplasty. Circulation. 1996;94:I615.
8. Bailey SR, O'Leary E, Chilton R. Angioscopic evaluation of site-specific administration of ReoPro. Catheter Cardiovasc Diagn. 1997;42:181-184.
9. Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv. 1999;48:211-213.
10. Sharma S, Bhambi B, Nyitray W, et al. Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure. J Cardiovasc Pharmacol Therap. 2003;8:9-15.
11. Schlaifer JD, Horgan W, Malkowski MJ. Acute thrombotic occlusion of the left main coronary artery in a hypercoagulable patient treated with intracoronary abciximab. Clin Cardiol. 2001;24:788.
12. Thuraisingham S, Tan KH. Dissolution of thrombus formed during direct coronary angioplasty with a single 10 mg intracoronary bolus dose of abciximab. Int J Clin Pract. 1999;53:604-607.
13. Lee CH, Ho KT, Tan CH. Instant dissolution of intracoronary thrombus by abciximab. Int J Cardiol. 2005;104:102-103.
14. Sharma S, Bhambi B, Nyitray W, et al. Intragraft administration of abciximab and verapamil combined with direct stenting prevents slow-flow during saphenous vein graft percutaneous coronary interventions. Am J Cardiol. 2002;154H.
15. Wöhrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation. 2003;107:1840-1843.
16. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31-34.
17. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv. 2004;62:186-192.
18. Romagnoli E, Burzotta F, Trani C, et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol. 2005;105: 250-255.
19. Salloum J, Tharpe C, Vaughn D, Zhao DX. Release and elimination of soluble vocative factors during percutaneous coronary intervention of saphenous vein grafts: analysis using the PercuSurge Guardwire distal protection device. J Invasive Cardiol. 2005;17:575-579.
20. de Lemos J, Gibson CM, Antman EM, et al. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: observations from the TIMI 14 trial. Am Heart J. 2001; 141:592-598.
21. Prati F, Kwiatkowski P, Caroselli C, et al. Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: results of a prospective randomized study. Catheter Cardiovasc Interv. 2005;66: 165-169.
22. Petronio AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J. 2003;24:67-76.
23. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial and myocardial perfusion in ST elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000;101:239-243.
24. Collet JP, Montalescot G, Lesty C, et al. Disaggregation of in-vitro preformed platelet-rich clots by abciximab increases fibrin exposure and fibrinolysis. Arterioscler Thromb Vasc Biol. 2001;21:142-148.
25. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-167.
26. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb. 1997;17:528-535.
27. Gawaz M, Neumann FJ, Dickfeld T, et al. Vitronectin receptor mediates platelet adhesion to the luminal aspect of endothelial cells. Circulation. 1997;96:1809-1818.
28. Aymong ED, Curtis MJ, Youssef M, et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation. 2002;105:2981-2985.